Investors & Media
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The lead product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy. The second product candidate, SLATE-001, is a shared neoantigen (“off-the-shelf”) immunotherapy. The company has developed its product candidates using two key pillars—a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Copyright West LLC. Minimum 15 minutes delayed.